Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4226684 | 0.91 | DRD4 (0.50) | DRD4UTS2RCCR3SIGMAR1S1PR1 | |
| SCHEMBL4215942 | 0.81 | CCR3 (0.59) | DRD4CCR3SIGMAR1KCNH2MCHR1 | |
| SCHEMBL4215947 | 0.81 | CCR3 (0.59) | DRD4CCR3SIGMAR1KCNH2MCHR1 | |
| SCHEMBL4220802 | 0.79 | CCR3 (0.40) | DRD4UTS2RCCR3S1PR5MCHR1 | |
| SCHEMBL4220091 | 0.79 | DRD4 (0.45) | DRD4CCR3SIGMAR1KCNH2S1PR5 | |
| SCHEMBL4496189 | 0.78 | DRD4 (0.51) | DRD4CCR3SIGMAR1S1PR1HTR2A | |
| SCHEMBL4224847 | 0.74 | CCR3 (0.41) | DRD4UTS2RCCR3S1PR5SMN1; SMN2 | |
| SCHEMBL5832363 | 0.73 | CCR3 (0.62) | DRD4CCR3SIGMAR1KCNH2MAPK1 | |
| SCHEMBL4226689 | 0.72 | CCR3 (0.60) | DRD4CCR3SIGMAR1S1PR1HTR2A | |
| SCHEMBL4226695 | 0.72 | CCR3 (0.60) | DRD4CCR3SIGMAR1S1PR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1919884-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | AstraZeneca AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007011292-A1 | N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118288-A1 | N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor | CCR3, CCR1, CCR5 | DRD4 1107/4885UTS2R 476/4885CCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.